contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-to-publish-financial-statements-2025-on-5-march-2026-invitation-to-webcast-presentation

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Cell therapies for Parkinson’s disease are progressing in Japan.                   Nikkei Asia              Japan panel approves world's first iPS cell-based therapies    Parkinson's and heart disease treatments available 20 years on from breakthrough                              “The committee also approved Amchepry, a candidate treatment for Parkinson’s disease developed by Japanese drugmaker Sumitomo Pharma.”   “To deliver treatments as quickly as possible, both products have been granted conditional and time-limited approval based on the likelihood of their efficacy, allowing them to be sold provisionally. Further testing will be needed to demonstrate safety and efficacy, and the companies will need to apply for ongoing approval within seven years.”

Siltanen has written about how Herantis has been selected as a recipient of 8 million euros in funding from the Horizon Europe 2025 program.  The news is very positive, as this non-dilutive funding covers a significant portion of the Phase II clinical trial for the HER-096 drug candidate, the total costs of which we estimate at 15–20 MEUR. The funding decision strengthens the company’s financial position and substantially reduces the downward pressure on the share price caused by a large dilutive share issue. We will update our forecasts to account for the new funding as well as the previous 4.2 MEUR share issue no later than in connection with the H2’25 report.                   Inderes              Herantis sai 8 MEUR:n EU-rahoituksen vaiheen II tutkimukseen - Inderes    Yhtiö on turvannut ison osan tutkimuksen rahoituksesta.

HORIZON EUROPE 2026 Antti Vuolanto, CEO of Herantis Pharma, said: “We are absolutely delighted to have been selected for this non-dilutive funding from Horizon Europe. This grant will make a meaningful contribution to the funding of our Phase 2 proof-of-concept study for HER-096, the resourcing of which we are continuing to discuss with potential investors and strategic partners. Being selected from a highly competitive field of innovative European companies further validates our scientific approach and underscores the potential of HER-096 to improve outcomes for people living with Parkinson’s disease. I would like to thank the European Commission for its support and look forward to providing further updates once the agreement is signed, and the study design has been finalized.” The ‘Boosting the translation of biotech research into innovative health therapies’ topic, which forms part of the wider Horizon Europe 2025 Health initiative, is designed to accelerate the translation of promising biotech research into clinical development and aims to deliver the following outcomes:  Faster access to innovative therapies for healthcare providers, researchers and patients Increased number of clinical trials evaluating novel biotech therapeutic approaches conducted within the European Union Strengthened competitiveness of small and medium-size enterprises (SMEs) in the EU and Associated Countries within the health biotech sector  More information on the Horizon Europe Health initiative can be found here. For more information, please contact: Herantis Pharma: Antti Vuolanto, CEO Tel: +358407517329

I dug up these figures from the 2024 financial statements:  Personnel expenses decreased to 1.5 (1.7) million euros due to lower personnel incentive bonuses. Other operating expenses increased by 1.7 million euros from 2023 (3.4 million euros), totaling 5.1 million euros in 2024. This increase is due to expenses related to the implementation of the Phase 1b clinical trial, drug candidate manufacturing costs related to the Phase 1b trial and preparation for the Phase 2 trial, as well as expenses related to the development of HER-096 biomarkers. Research and development expenses for 2024 were 3.6 (2.7) million euros. They were recorded in the income statement under other operating expenses and personnel expenses for the period.  Personnel expenses approx. 1.5 M and a total of 5.1 M in other trial preparation costs. However, it is mentioned there that drug candidate manufacturing costs for Phase II have already been included in that. Can it then be assumed that the 4M from the previous share issue would go mainly toward these personnel and preparation costs? In that case, roughly another 6M would still be needed, assuming 8M from Horizon and 6M from EIC, totaling 20M.

Working capital was not included in the 15-20 million. How much is it, i.e., the costs in addition to the trial for running the company normally? ”Herantis aims to launch a Phase 2 efficacy study during 2026. The cost estimate for the study is approximately 15–20 million euros, in addition to which the company requires working capital for the two-year project period. Herantis is currently evaluating different options for financing Phase 2: partnering with a large pharmaceutical company, equity financing, as well as research funding such as EU funding.”                   FIB – 10 Nov 25              Jäsenesittely: Herantis Pharma  – tavoitteena Parkinsonin taudin etenemisen...    Herantis Pharma on ottanut merkittävän askeleen kehittäessään uutta hoitoa HER-096, joka pyrkii hidastamaan ja lopulta pysäyttämään Parkinsonin taudin etenemisen. Yhtiön toimitusjohtaja Antti Vuolanto kertoo, miten Helsingin yliopiston spin-offista...

When talking about confidence in the candidate, this indicates quite strongly that there is confidence. Funding is unlikely to be a problem going forward – there is already evidence of efficacy based on this. I’m sure we’ll see another major pharmaceutical company in Finland alongside Orion.

Has Herantis provided an estimate of how much funding would be needed for the Phase II trials? There was an estimate like this in @Kulkuri’s earlier post here.  Now, there would be about 4M in cash from the previous share issue, 8M from Horizon 2025 funding, and I think it’s possible to get EIC funding at a 1:3 ratio of other funds raised up to a certain limit, if I remember correctly. So, those would total about 16M now, which hits the lower end of the estimate above. This will probably get Phase II started, but is anything more needed to see it through to completion?

Herantis Pharma

Herantis Pharma Plc – Press release 23 February, 2026 at 14:45 EETHerantis Pharma to publish financial statements 2025 on 5 March 2026 – invitation to webcast presentationEspoo, Finland, 23 ...

Herantis Pharma Plc – Press release 23 February, 2026 at 14:45 EETHerantis Pharma to publish financial statements 2025 on 5 March 2026 – invitation to webcast presentationEspoo, Finland, 23 February 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that it will publish its financial statements for 2025 on Thursday, 5 March 2026.Herantis CEO Antti Vuolanto and CFO Tone Kvåle will host a webcast relating to the report and current operations on Thursday, 5 March 2026, at 10:00 am EET (9:00 am CET). The presentation will be in English and will conclude with a Q&amp;A session. Questions can be submitted throughout the webcast event.Attendees are invited to register and join the online event using the following link: <a href="https://herantis.videosync.fi/q4-2025/register">https://herantis.videosync.fi/q4-2025/register</a>A recording of the webcast will be available on the Company’s website after the event has concluded: <a href="https://herantis.com/news-events/video-presentations/">https://herantis.com/news-events/video-presentations/</a>For more information, please contact:Herantis Pharma PlcTone Kvåle, CFO Tel: +47 915 19576 Email:&nbsp;<a href="mailto:ir@herantis.com">ir@herantis.com</a><a href="https://icrinc.com/what-we-do/healthcare/">ICR Healthcare</a> Sarah Elton-Farr, Stephanie Cuthbert, Phillip Marriage Tel: <a href="tel:+442037095700">+44 20 3709 5700</a> Email: <a href="mailto:herantispharma@icrhealthcare.com">herantispharma@icrhealthcare.com</a>Certified Advisor:UB Corporate Finance LtdTel: +358 9 25 380&nbsp;225Email:&nbsp;<a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>About Herantis Pharma PlcHerantis Pharma Plc is a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease. The Company’s lead product, HER-096, is a first-in-class small peptide that combines the neuroprotective mechanism of cerebral dopamine neurotrophic factor (CDNF), with the convenience of subcutaneous administration. In a Phase 1b clinical trial, HER 096 was shown to be generally safe and well tolerated in Parkinson’s disease patients. Herantis plans to advance HER-096 into a Phase 2 clinical trial in 2026 to evaluate efficacy, safety and tolerability in early-stage Parkinson’s patients.Herantis is listed on the Nasdaq First North Growth Market Finland.Company website:&nbsp;<a href="http://www.herantis.com/">www.herantis.com</a>